Isolation, identification and characterization of potentially novel antibiotics from rhizospheric bacteria without detectable in vitro resistance
从根际细菌中分离、鉴定和表征潜在的新型抗生素,且体外未检测到耐药性
基本信息
- 批准号:10358855
- 负责人:
- 金额:$ 44.36万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-15 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:AccountingAcinetobacterAnabolismAnti-Bacterial AgentsAntibiotic ResistanceAntibioticsAspartateBacteriaBacterial Antibiotic ResistanceBiochemicalBiological AssayBiotinCarbohydratesCenters for Disease Control and Prevention (U.S.)Cessation of lifeChemical StructureChemicalsClinicalCloningClustered Regularly Interspaced Short Palindromic RepeatsCollectionComplementCrude ExtractsCrystallizationDataDatabasesDevelopmentDisease ResistanceDrug resistanceDrug resistance in tuberculosisEpidemicEpithelial CellsErythrocytesEscherichia coliEventEvolutionExclusionFoundationsFutureGene ClusterGene Expression ProfilingGenesGenomeGoalsHealthHorizontal Gene TransferHousekeepingHumanHuman Cell LineIn VitroIndividualInfectionIntermediate resistanceLeadLinkLiquid ChromatographyMass Spectrum AnalysisMiningMolecularMolecular TargetMorbidity - disease rateMulti-Drug ResistanceMultiple Bacterial Drug ResistanceOrnithinePathway interactionsPatientsPovertyProductionPropertyProteinsProteomicsPseudomonas aeruginosaRNA methylationReporterReportingResearchResistanceRoleSamplingSeriesSignal TransductionSolidStaphylococcus aureusStreptomycesStructureStudentsSulfhydryl CompoundsSystemThin Layer ChromatographyTimeToxic effectVancomycinWorkWorld Health OrganizationYeastsbacterial resistancebaseclinically relevantcombatcomparativeexperimental studygene productgenome annotationgenome sequencinghomoserine lactonehuman mortalityin vivointestinal epitheliumknock-downknockout geneliquid chromatography mass spectrometrymethicillin resistant Staphylococcus aureusmicroorganism interactionmortalitymulti-drug resistant pathogenmutantnoveloverexpressionpathogenic bacteriapublic health relevancequorum sensingresistance generesistant strainresponsetranscriptome sequencingtranscriptomicswhole genome
项目摘要
ABSTRACT
Globally, approximately 2.8M people are infected with bacteria that are deemed resistant to clinically relevant
antibiotics an annual basis. Of these infections, 700,000 individuals will die with the United Sates accounting
for 5% (35,000) of these deaths. In the 2019 report, The World Health Organization states that if no action is
take, drug resistant diseases could cause 10 million deaths each year by 2050 and that by 2030, antibiotic
resistance could force up to 24 million people into extreme poverty. There is an urgent need for the
development of novel antibiotics to combat the drastic rise in the number of antibiotic resistant bacteria. In
particular, there are few molecules with broad spectrum activity against multidrug resistant pathogens. One of
the bottlenecks that is impeding the further development of novel antibiotics is the lack of identified gene
clusters producing them, which could lead to optimized heterologous production. The overarching goal of this
proposal is to identify and characterize the biosynthetic gene clusters and products from these anabolic
pathways that responsible for the production of antibiotics, which in crude extracts were shown to be active in
killing multi-drug resistant pathogens. The proposed research is significant since antibiotic resistance to
clinically relevant antibiotics is increasing across different types of pathogenic bacteria, and particularly,
broad-spectrum options to treat multidrug resistant strains are currently limited. The PI and his students
recently isolated and identified several strains of rhizospheric bacteria, which possess broad-spectrum
antibiotic activity. These initial experiments were performed using a culture-based approach, which screened
for strains competing against each other on solid media, leveraging the chemical ecological concept of
competition between bacterial species from the same environmental sample. One of the strains,
Exiguobacterium sp RIT 594 produces a cocktail of antibiotic compounds (in response to another isolate
Acinetobacter sp RIT 592). The antibiotic activity produce a >6 log reductions in three relevant resistant
clinical isolates: (1) the epidemic strain MRSA USA300 (FPR3757), (2) NDM-producing E. coli (MCR1_NJ)
and (3) VIM-producing P. aeruginosa (AR-0266) in 24 h time kill assays. Importantly, the preliminary data
show that the emergence of in vitro resistance was not detected in the time kill assays. Subsequent analysis of
crude extracts using LC-MS provided evidence and identified more than 200 novel compounds that are
unknown in the mass spectrometry databases. Whole genome sequencing and annotation, revealed 8 putative
gene clusters that contained a large number of uncharacterized proteins that are predicated to produce a
variety of secondary metabolites that are putatively endowed with antibiotic properties.
摘要
在全球范围内,大约有280万人感染了被认为对临床相关药物具有耐药性的细菌。
抗生素每年。在这些感染中,据美国统计,
占死亡人数的5%(35,000)。在2019年的报告中,世界卫生组织指出,如果不采取行动,
到2050年,抗药性疾病每年可能导致1000万人死亡,到2030年,抗生素
抵抗可能迫使多达2 400万人陷入极端贫困。迫切需要
开发新的抗生素,以对抗抗生素耐药性细菌数量的急剧上升。在
特别是,几乎没有对多药耐药病原体具有广谱活性的分子。之一
阻碍新型抗生素进一步开发的瓶颈是缺乏可识别的基因,
集群产生它们,这可能导致优化的异源生产。这个项目的首要目标是
建议是确定和表征这些合成代谢的生物合成基因簇和产物,
负责生产抗生素的途径,在粗提物中,抗生素在
杀死耐多药病原体。这项拟议的研究是重要的,因为抗生素耐药性,
临床上相关的抗生素在不同类型的病原菌中不断增加,特别是,
治疗多药耐药菌株的广谱选择目前是有限的。PI和他的学生
近年来分离鉴定了几株具有广谱性的根际细菌,
抗菌活性这些最初的实验是使用基于培养的方法进行的,
对于在固体培养基上相互竞争的菌株,利用化学生态学概念,
来自同一环境样品的细菌物种之间的竞争。其中一种菌株,
铜绿假单胞菌属RIT 594产生抗生素化合物的混合物(响应于另一种分离物
不动杆菌属RIT 592)。抗生素活性在三种相关耐药菌株中产生>6个对数减少,
临床分离株:(1)流行株MRSA USA 300(FPR 3757);大肠杆菌(MCR1_NJ)
和(3)在24小时时间杀灭测定中的VIM-产生铜绿假单胞菌(AR-0266)。重要的是,初步数据
表明在时间杀灭试验中没有检测到体外抗性的出现。的后续分析
使用LC-MS的粗提物提供了证据,并鉴定了200多种新化合物,
在质谱数据库中未知。全基因组测序和注释,揭示了8个推定的
基因簇含有大量的未表征的蛋白质,这些蛋白质被预测会产生一种
具有抗生素特性的各种次级代谢产物。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ANDRE O HUDSON其他文献
ANDRE O HUDSON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ANDRE O HUDSON', 18)}}的其他基金
Isolation, identification and characterization of potentially novel antibiotics from rhizospheric bacteria without detectable in vitro resistance
从根际细菌中分离、鉴定和表征潜在的新型抗生素,且体外未检测到耐药性
- 批准号:
10581945 - 财政年份:2021
- 资助金额:
$ 44.36万 - 项目类别:
Genetic and structural analysis of L,L-diaminopimelate aminotransferase (DapL): An attractive target for the development of narrow-spectrum antibiotics
L,L-二氨基庚二酸转氨酶 (DapL) 的遗传和结构分析:窄谱抗生素开发的一个有吸引力的靶点
- 批准号:
9513721 - 财政年份:2016
- 资助金额:
$ 44.36万 - 项目类别:
Genetic and structural analysis of L,L-diaminopimelate aminotransferase (DapL): An attractive target for the development of narrow-spectrum antibiotics
L,L-二氨基庚二酸转氨酶 (DapL) 的遗传和结构分析:窄谱抗生素开发的一个有吸引力的靶点
- 批准号:
9171013 - 财政年份:2016
- 资助金额:
$ 44.36万 - 项目类别:
Doctoral Training/Biochemistry/Transsulfuration Enzymes
博士培训/生物化学/转硫酶
- 批准号:
6935820 - 财政年份:2003
- 资助金额:
$ 44.36万 - 项目类别:
Doctoral Training/Biochemistry/Transsulfuration Enzymes
博士培训/生物化学/转硫酶
- 批准号:
6784030 - 财政年份:2003
- 资助金额:
$ 44.36万 - 项目类别:
Doctoral Training/Biochemistry/Transsulfuration Enzymes
博士培训/生物化学/转硫酶
- 批准号:
6695311 - 财政年份:2003
- 资助金额:
$ 44.36万 - 项目类别:
相似国自然基金
共生细菌Acinetobacter soli来源精氨酸级联味觉受体NlGR21介导褐飞虱抗烯啶虫胺的分子机制
- 批准号:JCZRYB202500693
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
细菌Acinetobacter sp.挥发物在瓜蚜蜜露调控龟纹瓢虫产卵定位中的作用研究
- 批准号:32302339
- 批准年份:2023
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
Acinetobacter sp. AS23菌株介导茶籽象耐受茶皂素毒性的分子机制解析
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 44.36万 - 项目类别:
Research Grant
Generative machine learning for narrow spectrum antibiotic discovery against Acinetobacter baumannii
生成机器学习用于发现针对鲍曼不动杆菌的窄谱抗生素
- 批准号:
477936 - 财政年份:2023
- 资助金额:
$ 44.36万 - 项目类别:
Operating Grants
Conserved structural dynamics of outer-membrane channels in Acinetobacter baumannii as potential drug targets
鲍曼不动杆菌外膜通道的保守结构动力学作为潜在的药物靶点
- 批准号:
494854 - 财政年份:2023
- 资助金额:
$ 44.36万 - 项目类别:
Operating Grants
Defining key players at the host-pathogen interface during Acinetobacter baumannii infection
定义鲍曼不动杆菌感染期间宿主-病原体界面的关键参与者
- 批准号:
488684 - 财政年份:2023
- 资助金额:
$ 44.36万 - 项目类别:
Operating Grants
Study of clinically over-expressed and chimeric RND multidrug efflux pumps from Acinetobacter baumannii and Pseudomonas aeruginosa
鲍曼不动杆菌和铜绿假单胞菌临床过表达和嵌合 RND 多药外排泵的研究
- 批准号:
23K14346 - 财政年份:2023
- 资助金额:
$ 44.36万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Biomimetic Macrophage Membrane-Coated Nanosponges: A Novel Therapeutic for Multidrug-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii Hospital-Associated Pneumonia
仿生巨噬细胞膜包被的纳米海绵:一种治疗多重耐药铜绿假单胞菌和鲍曼不动杆菌医院相关肺炎的新疗法
- 批准号:
10674406 - 财政年份:2023
- 资助金额:
$ 44.36万 - 项目类别:
Using strain history to improve prediction of the evolution of antimicrobial resistance in Acinetobacter baumannii
利用菌株历史改进对鲍曼不动杆菌抗菌药物耐药性演变的预测
- 批准号:
10677362 - 财政年份:2023
- 资助金额:
$ 44.36万 - 项目类别:
Inhibitors of adaptive efflux mediated resistance in Acinetobacter baumannii
鲍曼不动杆菌适应性外排介导的耐药性抑制剂
- 批准号:
10625029 - 财政年份:2023
- 资助金额:
$ 44.36万 - 项目类别:
Creation of Active Substances from Deep-sea Actinomycetes to Disrupt Drug-Resistant Acinetobacter spp.
从深海放线菌中产生活性物质来破坏耐药不动杆菌属。
- 批准号:
22K19442 - 财政年份:2022
- 资助金额:
$ 44.36万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Identifying niche specific adaptations in Acinetobacter baumannii
鉴定鲍曼不动杆菌的生态位特异性适应
- 批准号:
10449699 - 财政年份:2022
- 资助金额:
$ 44.36万 - 项目类别: